Chemocentryx reported $-39209000 in Net Income for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 766M 2787M
Alexion Pharmaceuticals ALXN:US $ 636M 100.2M
Alnylam Pharmaceuticals ALNY:US $ -189.56M 10.73M
Amgen AMGN:US $ 464M 1182M
AstraZeneca AZN:LN 550M 1011M
Bayer BAYN:GR € -2335M 4424M
Biogen BIIB:US $ 448.5M 38.3M
Biomarin Pharmaceutical BMRN:US $ 12.94M 4.43M
Bristol Myers Squibb BMY:US $ 1055M 966M
Chemocentryx CCXI:US $ -39.21M 9.5M
GlaxoSmithKline GSK:LN 1395M 322M
Glaxosmithkline GSK:US $ 1395M 322M
Johnson & Johnson JNJ:US $ 6278M 81M
Macrogenics MGNX:US $ -39.94M 11.34M
Merk MRK:US $ 1545M 1634M
Mirati Therapeutics MRTX:US $ -166.43M 30.75M
Novartis NOVN:VX SF 2896M 837M
Omeros OMER:US $ -28593000 6.5M
Pfizer PFE:US $ 5564M 686M
Sarepta Therapeutics SRPT:US $ -81.4M 85.84M
Takeda 4502:JP Y 200377M 3279M
Teva Pharmaceutical TEVA:IT 207M 129M
YTE INCY:US $ 149.46M 95.92M